0000000000467634

AUTHOR

Gaetano Tortorella

showing 2 related works from this author

Mutation spectrum of NF1 gene in Italian patients with neurofibromatosis type 1 using Ion Torrent PGM™ platform

2017

Neurofibromatosis type 1 (NF1) is caused by mutations of the NF1 gene and is one of the most common human autosomal dominant disorders. The patient shows different signs on the skin and other organs from early childhood. The best known are six or more café au lait spots, axillary or inguinal freckling, increased risk of developing benign nerve sheath tumours and plexiform neurofibromas. Mutation detection is complex, due to the large gene size, the large variety of mutations and the presence of pseudogenes. Using Ion Torrent PGM™ Platform, 73 mutations were identified in 79 NF1 Italian patients, 51% of which turned out to be novel mutations. Pathogenic status of each variant was classifi…

Male0301 basic medicineDNA Mutational Analysismedicine.disease_causeChildGenetics (clinical)Sanger sequencingGeneticsMutationNeurofibromin 1biologyMosaicismCafe-au-Lait SpotsNeurofibromatosis type 1; Legius's syndrome; Next generation sequencingGeneral MedicineMiddle AgedItalyChild PreschoolsymbolsMedical geneticsFemalemedicine.symptomHumanAdultmedicine.medical_specialtyNeurofibromatosis 1AdolescentPseudogeneDNA Mutational Analysi03 medical and health sciencessymbols.namesakeGeneticNext generation sequencingCafé au lait spotSkin AbnormalitieGeneticsmedicineHumansCafe-au-Lait SpotNeurofibromatosisLegius's syndromeInfantSequence Analysis DNAIon semiconductor sequencingmedicine.diseaseNeurofibromin 1030104 developmental biologyMutationSkin Abnormalitiesbiology.proteinNeurofibromatosis type 1European Journal of Medical Genetics
researchProduct

Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy

2004

Purpose: To evaluate the efficacy and safety of levetiracetam (LEV) in refractory crypto/symptomatic, partial or generalised epilepsy in children, adolescents and young adults. Methods: We performed a prospective open label add-on study in 99 patients (age 12 months to 32 years, mean 14 years) with partial or generalised, crypto/symtpomatic seizures. Levetiracetam was added to no more than two baseline AEDs and the efficacy was rated according to seizure type and frequency. Results: LEV was initiated at the starting dose of 10 mg/kg/day with 5-day increments up to 50 mg/kg/day, unless it was not tolerated. Concomitant therapy was generally not modified throughout the study. After a mean fol…

AdultMalePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentlevetiracetamefficacyIrritabilityStatistics NonparametricEpilepsyDOUBLE-BLINDantiepileptic drugmedicineHumansprospective trialProspective StudiesChildAdverse effectChi-Square DistributionEpilepsybusiness.industryInfantmedicine.diseasePiracetamAnticonvulsantNeurologyTolerabilityEpilepsy in childrenChild PreschoolAnesthesiaEpilepsy syndromesFemaleTRIALNeurology (clinical)Levetiracetammedicine.symptomtolerability PARTIAL SEIZURESbusinessFollow-Up Studiesmedicine.drug
researchProduct